Chronic Myelogenous Leukemia (CML)

- No Circulating Blasts <= 5% Blasts in BM
  - Mismatched Unrelated
    - BMT391
      Phase II
      HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide in Hematologic Malignancies
      PI: Arai
      Sponsor: National Marrow Donor Program (NMDP)
    - BMT342
      Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
      PI: Johnston
      Sponsor: Fred Hutchinson
  - CR
    - None at this Time
- Optional Path
  - Trial Posting
  - Link
  - Enrolment on Hold
  - Extension Study
  - Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu